Therapeutics News

Biological drugs have a small to moderate effect in reducing fatigue in patients with psoriasis vulgaris, but research is needed to understand the underlying causes in this relationship.

Dupilumab decreased the risk for serious or severe infection and nonherpetic skin infections in patients with moderate to severe atopic dermatitis compared with placebo, according to results published in the American Journal of Clinical Dermatology.

Patients with moderate-to-severe psoriasis who failed treatment with an IL-17A agent, had significant disease improvement with brodalumab, according to Grace Kimmel, MD, of the Icahn School of Medicine at Mount Sinai, and colleagues.

Long-term treatment adherence to secukinumab among patients with psoriasis appears to be favorable, with 24% of patients discontinuing treatment over the follow-up period of one study.

Researchers from Stanford University discovered new regional dermatoses mainly on the face in a cohort of adults with atopic dermatitis taking dupilumab, in the most popular Healio Dermatology research news from the past week.

The endocannabinoid system is functional in the skin, responsible for many aspects of skin homeostasis, and offers potential targets for the management of inflammatory skin conditions, according to a literature review.

Adults with moderate to severe alopecia areata treated with cyclosporin had a greater reduction in Severity of Alopecia Tool score over time when compared with a placebo group, according to a study.

In a cohort of adults with atopic dermatitis who were taking dupilumab, nearly a quarter of patients developed new regional dermatoses appearing mostly on the face.

Novartis, along with biopharmaceutical companies MorphoSys and Galapagos, announced the initiation of GECKO, a phase 2 study exploring a subcutaneous formulation of MOR106 combined with topical corticosteroids in patients with moderate to severe atopic dermatitis.

Bausch Health Companies announced that the FDA has accepted its new drug application for Duobrii lotion in the topical treatment of plaque psoriasis in adults.